脑鞘氨醇-1-磷酸受体：FTY720在多发性硬化治疗中的意义。
Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
作者信息
Dev Kumlesh K, Mullershausen Florian, Mattes Henri, Kuhn Rainer R, Bilbe Graeme, Hoyer Daniel, Mir Anis
机构信息
Department of Anatomy and Neuroscience, University College Cork, Windle Building, Cork, Ireland.
出版信息
Pharmacol Ther. 2008 Jan;117(1):77-93. doi: 10.1016/j.pharmthera.2007.08.005. Epub 2007 Sep 8.
Multiple sclerosis (MS) is an autoimmune, neurological disability with unknown etiology. The current therapies available for MS work by an immunomodulatory action, preventing T-cell- and macrophage-mediated destruction of brain-resident oligodendrocytes and axonal loss. Recently, FTY720 (fingolimod) was shown to significantly reduce relapse rates in MS patients and is currently in Phase III clinical trials. This drug attenuates trafficking of harmful T cells entering the brain by regulating sphingosine-1-phosphate (S1P) receptors. Here, we outline the direct roles that S1P receptors play in the central nervous system (CNS) and discuss additional modalities by which FTY720 may provide direct neuroprotection in MS.
多发性硬化症（MS）是一种病因不明的自身免疫性神经疾病。目前用于治疗MS的疗法通过免疫调节作用发挥功效，可防止T细胞和巨噬细胞介导的脑内少突胶质细胞破坏及轴突损失。最近，FTY720（芬戈莫德）被证明能显著降低MS患者的复发率，目前正处于III期临床试验阶段。该药物通过调节1-磷酸鞘氨醇（S1P）受体，减少有害T细胞进入大脑的迁移。在此，我们概述了S1P受体在中枢神经系统（CNS）中所起的直接作用，并讨论了FTY720可能在MS中提供直接神经保护的其他方式。
Zotero 插件